AASLD’s educational programming at DDW® is designed to provide a broad education in liver disease for the general gastroenterologist, according to AASLD Secretary Kimberly A. Brown, MD, FAASLD.
“For the physicians and mid-levels with some hepatology in their practice, I would advise them to start by attending Hepatology Update on Saturday (May 6),” said Dr. Brown, chief of the division of gastroenterology and hepatology at Henry Ford Health System, Detroit, MI. “This session provides a great overview for the practitioner who wants a broad base of new information.”
The annual Hepatology Update: The Year in Review postgraduate course will provide a comprehensive overview of recent advances in hepatology. Speakers will emphasize recently published papers expected to alter practice as well as basic science discoveries that have or may have clinical implications.
AASLD’s clinical symposia will provide more in-depth information in several areas of hepatology beginning Sunday, May 7.
The symposium The Hospitalized Cirrhotic: Evidence-Based Management, which will be held Monday, May 8, will focus on the interaction between portal hypertensive circulatory and renal changes and their complications and management.
“Many gastroenterologists will have to manage cirrhotic patients in the hospital. This is a good overview of some of the treatment and management challenges they’ll face in that population,” Dr. Brown said.
Other AASLD clinical symposia will cover topics like fatty liver disease, complications of portal hypertension, alcoholic liver disease and liver cancer. Several parallel sessions, each one featuring a collection of abstracts on a particular topic, will focus on viral hepatitis C and B, fatty liver disease, complications of cirrhosis, and pediatric diseases, to name just a few. There are also several state-of-the-art lectures in the AASLD program.
On Sunday, Michael W. Fried, MD, FAASLD, will discuss factors that may influence response rates of antiviral regimens and review strategies that have been demonstrated to maximize patient outcomes during his state-of-the-art lecture Hepatitis C: If One Pill Cures All, Why Aren’t All Patients Cured? Dr. Fried is professor of medicine and director of the UNC Liver Center at the University of North Carolina School of Medicine, Chapel Hill.
Also on Sunday, Zobair M. Younossi, MD, MPH, FAASLD, will examine the treatment of non-alcoholic fatty liver disease as well as the patient-reported clinical outcomes and economic burdens of the disease during his state-of-the-art lecture NASH: Does My Liver Look Fat? Dr. Younossi is vice president for research of Inova Health System, Falls Church, VA, professor of medicine at Virginia Commonwealth University, Inova Campus, and affiliate professor of biomedical sciences at George Mason University.
“Both are outstanding speakers, and those are really interesting topics for everybody attending DDW,” Dr. Brown said.
Paul B. Watkins, MD, FAASLD, will discuss drug-induced liver injury on Sunday during a state-of-the-art lecture titled DILI: Is this Pill Safe to Swallow? Dr. Watkins is director of the University of North Carolina Institute for Drug Safety Sciences and professor of medicine, pharmacy and public health at the University of North Carolina, Chapel Hill.
On Monday, AASLD President Anna S. Lok, MD, FAASLD, will update attendees on current therapies for hepatitis B and the need for new treatment regimens during her state-of-the-art lecture Hepatitis B Treatment: Current Status and Prospects For a Cure. Dr. Lok is the Alice Lorhman Andrews Research Professor in Hepatology in the department of internal medicine at the University of Michigan Health System, Ann Arbor.